Vaxxinity, Inc. (VAXX)
| Market Cap | 12.68K |
| Revenue (ttm) | n/a |
| Net Income | -56.93M |
| EPS | -0.45 |
| Shares Out | 126.75M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 16,116 |
| Open | 0.0001 |
| Previous Close | 0.0001 |
| Day's Range | 0.0001 - 0.0001 |
| 52-Week Range | 0.000001 - 0.2000 |
| Beta | -74.42 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | n/a |
About Vaxxinity
Vaxxinity, Inc., a biotechnology company, focuses on developing product candidates for human use in the fields of neurology, cardiovascular diseases, and coronaviruses in the United States. Its product pipeline comprises UB-311, which is in phase 2 clinical trial that targets toxic forms of aggregated amyloid-b in the brain to fight alzheimer’s disease; UB-312, which is in phase 1 clinical trial that targets toxic forms of aggregated α-synuclein in the brain to fight parkinson’s disease and other synucleinopathies, such as Lewy body dementia an... [Read more]
Financial Performance
Financial StatementsNews
Vaxxinity’s Parkinson’s candidate UB-312 demonstrates efficacy in publication
Vaxxinity announced that Nature Medicine has published exploratory data from the company’s Phase 1 clinical trial of UB-312 in patients with Parkinson’s disease. The trial included measures of clinica...
Vaxxinity UB-312 Parkinson's Trial Results Published in Nature Medicine
UB-312 is the first Parkinson's candidate to reduce pathology as measured by a seed amplification assay, and suggest clinical improvement on motor experiences of daily living.
Vaxxinity Issues Shareholder Letter
CAPE CANAVERAL, Fla., April 19, 2024 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (“Vaxxinity”, “we”, “us” or the “Company”) (Nasdaq: VAXX), a U.S. company pioneering the development of a new class of medicine...
Vaxxinity to voluntarily delist, deregister its Class A common stock
Vaxxinity announced its intention to voluntarily delist from the Nasdaq Global Market and to deregister its Class A common stock under Section 12(b) and Section 12(g) of the Securities Exchange…
Vaxxinity Announces Intention to Voluntarily Delist and Deregister its Class A Common Stock
CAPE CANAVERAL, Fla., April 19, 2024 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (“Vaxxinity”, “we”, “us” or the “Company”) (Nasdaq: VAXX), a U.S. company pioneering the development of a new class of medicine...
Vaxxinity to Present Clinical Data at the Annual Academy of Neurology 2024 Annual Meeting
Presentation will address the Company's clinical data in Parkinson's disease Presentation will address the Company's clinical data in Parkinson's disease
Vaxxinity Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Corporate Updates
CAPE CANAVERAL, Fla., March 27, 2024 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company pioneering the development of a new class of immunotherapeutic vaccines, today reported financia...
Vaxxinity Annual report: Q4 2023
Vaxxinity has published its Q4 2023 annual report on March 27, 2024.
Vaxxinity Press release: Q4 2023
Vaxxinity issued a press release on March 27, 2024, disclosing material business information to investors.
Vaxxinity Slides: Corporate Presentation
Vaxxinity has posted slides in relation to its latest quarterly earnings report, which was published on March 12, 2024.
Vaxxinity announces ‘positive’ target engagement data from Phase 1 trial
Vaxxinity announced “positive” clinical data from its UB-312 program in Parkinson’s disease, or PD, presented by Jean-Cosme Dodart, PhD, SVP of Research at Vaxxinity in an oral session at the…
Vaxxinity Announces Positive Target Engagement Data from Phase 1 Clinical Trial for Parkinson's Disease at AD/PD™ 2024
UB-312 is first immunotherapy to show reduction of pathological alpha-synuclein in cerebrospinal fluid of Parkinson's patients UB-312 is first immunotherapy to show reduction of pathological alpha-syn...
Vaxxinity announces publication of data on VXX-401
Vaxxinity announced the publication of data from multiple non-human primate studies demonstrating that VXX-401 reproducibly lowers low-density lipoprotein cholesterol in non-human primates. The result...
Vaxxinity's Cholesterol Vaccine Candidate Successfully Lowers LDL-C: Preclinical Data Published
Preclinical data published in the Journal of Lipid Research indicate VXX-401 is well-tolerated, with no safety signals observed, and robustly reduces LDL-C in cynomolgus monkeys.
Vaxxinity to Present Clinical and Preclinical Pipeline Data at AD/PD 2024
CAPE CANAVERAL, Fla., Feb. 13, 2024 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company pioneering the development of a new class of medicines, today announced it will present clinical ...
Vaxxinity announces research collaboration with CTRND
Vaxxinity announced a research collaboration with the University of Florida’s Center for Translational Research in Neurodegenerative Disease, CTRND, to support its work on the development of vaccines ...
Vaxxinity Announces Research Collaboration on Active Immunotherapies for Neurodegenerative Diseases with University of Florida
CAPE CANAVERAL, Fla., Jan. 30, 2024 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company pioneering the development of a new class of medicines, today announced a research collaboration ...
Vaxxinity Slides: Corporate Presentation
Vaxxinity has posted slides in relation to its latest quarterly earnings report, which was published on January 19, 2024.
Vaxxinity announces collaboration on space medicine research with UCF
Vaxxinity announced a collaboration with the University of Central Florida, UCF, to advance space medicine research. The research, funded by a grant from the State of Florida, aims to further…
Vaxxinity Announces Collaboration on Space Medicine Research with University of Central Florida
CAPE CANAVERAL, Fla., Jan. 18, 2024 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company pioneering the development of a new class of medicines, today announced a collaboration with the...
Vaxxinity to Present at the 2024 J.P. Morgan Healthcare Conference
CAPE CANAVERAL, Fla., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company pioneering the development of a new class of medicines, today announced that Mei Mei Hu, Chief Ex...
Vaxxinity to Present at Upcoming November Medical and Investor Conferences
CAPE CANAVERAL, Fla., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company pioneering the development of a new class of medicines, today announced that its scientists and e...
Vaxxinity Quarterly report: Q3 2023
Vaxxinity has published its Q3 2023 quarterly earnings report on November 8, 2023.
Vaxxinity Press release: Q3 2023
Vaxxinity issued a press release on November 8, 2023, disclosing material business information to investors.
Vaxxinity reports Q3 EPS (10c), consensus (12c)
“We continue to advance our clinical programs and to validate our platform with the goal of addressing major chronic diseases with more convenient, cost-effective, and accessible immunotherapies world...